Fundraising March 15, 2025 – April 1, 2025 About fundraising

Terms search

26
Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial
Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A. Birkmeier; Klaus Tiroch; Robert A. Byrne; Albert Schömig; Adnan Kastrati
28
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial
Stefanie Schulz; K. Anette Birkmeier; Gjin Ndrepepa; Werner Moshage; Franz Dotzer; Kurt Huber; Josef Dirschinger; Melchior Seyfarth; Albert Schömig; Adnan Kastrati; Julinda Mehilli
33
Predictive Factors of Restenosis After Coronary Stent Placement
Adnan Kastrati MD; Albert Schömig MD; Shpend Elezi MD; Helmut Schühlen MD; Josef Dirschinger MD; Martin Hadamitzky MD; Anne Wehinger MD; Jörg Hausleiter MD; Hanna Walter MD; Franz-Josef Neumann MD
36
Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients
K. Anette Birkmeier; Adnan Kastrati; Robert A. Byrne; Heidrun Holle; Stefanie Schulz; Klaus Tiroch; Sebastian Kufner; Steffen Massberg; Karl-Ludwig Laugwitz; Albert Schömig; Julinda Mehilli
40
Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial
Adnan Kastrati; Julinda Mehilli; Josef Dirschinger; Ullrich Schricke; Jodi Neverve; Jürgen Pache; Stefan Martinoff; Franz-Josef Neumann; Stephan Nekolla; Rudolf Blasini; Melchior Seyfarth; Markus Schw
42
Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: Final results of the intracoronary stenting and angiographic restenosis – test equivalence between two drug-eluting stents (ISAR-TEST) trial
Lamin King; Robert A. Byrne; Julinda Mehilli; Albert Schömig; Adnan Kastrati; Jurgen Pache
43
Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials
Alban Dibra; Klaus Tiroch; Stefanie Schulz; Henning Kelbæk; Christian Spaulding; Gerrit J. Laarman; Marco Valgimigli; Emilio Di Lorenzo; Christoph Kaiser; Ilkka Tierala; Julinda Mehilli; Gianluca Camp
44
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment
Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Franz-Josef Neumann; Stefanie Schulz; Jurriën ten Berg; Olga Bruskina; Franz Dotzer; Josef Dirschinger; Peter B. Berger; Albert Schömig; Adnan Kastrati
47
Short- and long-term clinical outcome after various stent implantation: Overview of the results of uni- and multicenter stent registries
Mariann Gyöngyösi; Aliashgar Khorsand; Wolfgang Sperker; Christoph Strehblow; Paul Wexberg; Peter Probst; Peter Siostrzonek; Irene Lang; Heinz Sochor; Dietmar Glogar
48
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Sibbing; D.; Koch; W.; Gebhard; D.; Schuster; T.; Braun; S.; Stegherr; J.; Morath; T.; Schomig; A.; von Beckerath; N.; Kastrati; A
49
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT—A double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel
Helmut Schühlen; Adnan Kastrati; Julinda Mehilli; Jörg Hausleiter; Josef Dirschinger; Franz Dotzer; Hildegard Bollwein; Albert Schömig